Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- UOA3-1493
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(17)30404-7
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 929
- Volume
- 18
- Issue
- 7
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
23
- Research group(s)
-
A - Nursing and Allied Health
- Citation count
- 31
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the conception and design of the study,Contribution to the organisation of the conduct of the study,Contribution to carrying out the study,Contribution to analysis and interpretation of the study data
Contribution B: The author helped draft the output,Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -